GILD.SW Gilead Sciences (SIX) up 73.91% to CHF114.78 on 17 Mar 2026: trend check

GILD.SW stock led Swiss trading on 17 Mar 2026 after Gilead Sciences, Inc. (GILD.SW) closed at CHF114.78, a +73.91% jump (+48.78) from the previous close of CHF66.00 on the SIX exchange in Switzerland. The move registered on an intraday volume of 66 shares against a 50-day average of 128,237, underlining unusually low liquidity accompanying a large price change. Investors should note the sharp gap and mix it with fundamentals: Gilead’s reported EPS of 5.38 and a P/E around 21.35 remain central to valuation debate. Meyka AI’s snapshot flags the trade as a top gainer event with technical and liquidity caveats

GILD.SW stock: price action and immediate drivers

GILD.SW stock closed at CHF114.78 on 17 Mar 2026, up 73.91% from CHF66.00. The advance of CHF48.78 occurred on just 66 shares, far below the average daily volume of 128,237, which suggests the move was amplified by low liquidity and concentrated orders rather than broad market participation.

There was no official earnings release tied to the spike. Traders cited sector rotation into Healthcare and near-term speculative flows as likely contributors. We link the company website for primary disclosure: Gilead investor site.

GILD.SW stock: fundamentals and valuation snapshot

Gilead Sciences, Inc. (GILD.SW) shows trailing EPS of 5.38 and a reported P/E of 21.35 on the SIX listing in CHF. Enterprise value to EBITDA is 2.01, return on equity is 25.96%, and debt to equity is 1.27, reflecting a leveraged balance sheet alongside strong profitability.

Key per-share metrics include revenue per share 14.74, book value per share 12.48, and cash per share 4.16. These figures indicate solid cash generation but a premium versus book value (price-to-book 5.26) that investors must weigh when assessing the rally.

GILD.SW stock: technicals, liquidity and sector context

Technically, the entire quoted profile shows identical averages (50-day and 200-day) at CHF114.78 because today’s price reset short-term references. The tiny trade volume of 66 versus average volume 128,237 gives a relative volume of 0.00, amplifying volatility risk for intraday traders.

In sector context, Healthcare on the SIX has an average P/E around 29.41 and net margin near 19.81%. Gilead’s P/E of 21.35 is lower than the sector average, which partly explains why some value-oriented funds monitor Gilead for rotation opportunities despite short-term noise.

GILD.SW stock: Meyka AI grade and model forecast

Meyka AI rates GILD.SW with a score out of 100: Score: 67.57 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and are for informational purposes only.

Meyka AI’s forecast model projects CHF128.50 as a 12-month reference price for GILD.SW stock, implying an upside of +11.93% from the close at CHF114.78. Forecasts are model-based projections and not guarantees.

GILD.SW stock: realistic price targets and analyst-style scenarios

We frame three scenario targets for risk management: a conservative target CHF95.00 (down -17.16%), base-case CHF125.00 (up +8.91%), and bull-case CHF150.00 (up +30.72%). Price targets reflect valuation ranges using P/E multiples of 17.0–27.0, applied to trailing EPS 5.38 and taking into account net debt and enterprise value.

Institutional analysts often set intermediate targets near CHF120–CHF135 based on product sales stability and pipeline optionality. Traders should adjust position sizes for the marked liquidity volatility observed on SIX today.

GILD.SW stock: catalysts and risks to monitor

Potential near-term catalysts include updates on oncology assets, new regulatory approvals, partnership trial readouts, and any corporate capital actions disclosed by Gilead. Positive clinical data or licensing deals would support valuation re-rating.

Key risks include patent expiries on core HIV therapies, pricing pressure, competitive launches, and the leverage profile (debt/equity 1.27). The market reaction today amplifies headline risk: price can reverse quickly on thin liquidity, so risk controls are essential.

Final Thoughts

GILD.SW stock was the top gainer on the SIX on 17 Mar 2026, closing at CHF114.78 after a +73.91% surge on extremely low volume. The move reflects liquidity-driven volatility rather than an immediate change in Gilead’s core fundamentals. Fundamentals remain mixed but solid: trailing EPS 5.38, P/E 21.35, EV/EBITDA 2.01, and ROE 25.96%. Meyka AI rates GILD.SW 67.57/100 (B, HOLD) and projects a model price of CHF128.50, implying +11.93% upside from today’s close. That forecast assumes no major adverse regulatory news and steady product sales. Investors should treat today’s gap as a trading event and align positions to scenario targets: conservative CHF95.00, base CHF125.00, bull CHF150.00. Use tight size limits given the tiny volume of 66 shares traded; the price can swing significantly on limited order flow. For primary disclosures visit the company site and for ongoing monitoring use our Meyka AI-powered market analysis tools on the Meyka stock page for GILD.SW: GILD.SW on Meyka. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.